marstacimab-hncq

FDA Drug Profile — HYMPAVZI

marstacimab-hncq is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including HYMPAVZI. Available dosage form: injection, solution.

Drug Details

Generic Name
marstacimab-hncq
Brand Names
HYMPAVZI
Application Number
BLA761369
Sponsor
Pfizer Laboratories Div Pfizer Inc
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
MARSTACIMAB

Indications and Usage

1 INDICATIONS AND USAGE HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. ( 1 )